{"groups":[{"description":"Patients receive celecoxib PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.","id":"FG000","title":"Arm I (Celecoxib)"},{"description":"Patients receive placebo PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.","id":"FG001","title":"Arm II (Placebo)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"12"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"12"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"There were no significant events or approaches utilized following enrollment but prior to group assignment.","recruitmentDetails":"23 asymptomatic adult patients with a serum monoclonal protein \\>1g/dL from Cleveland Clinic, Mayo Clinic, or University of Arkansas Medical Center were randomized between August 2005 and April 2008"}